---
title: "ContraBand pulmonary artery banding system gains US FDA breakthrough status for HFrEF treatment"
date: "2024-07-23T08:43:59.000Z"
publishedDate: "23 juillet 2024"
summary: "Restore Medical has been granted breakthrough device designation by the US Food and Drug Administration (FDA) for its ContraBand device. The designation is specifically for treatment of heart failure with reduced ejection fraction (HFrEF) patients who remain symptomatic despite maximally tolerated guideline-directed medical therapy, without significant pulmonary hypertension or right heart failure."
importance: ""
sourceUrl: "https://cardiovascularnews.com/contraband-pulmonary-artery-banding-system-fda-breakthrough/"
tags: ["France", "Actualité", "Cardiovascular News — Latest"]
permalink: "/papers/2024-07-23-contraband-pulmonary-artery-banding-system-gains-us-fda-breakthrough-status-for-hfref-treatment"
imageUrl: "https://cardiovascularnews.com/wp-content/uploads/sites/14/2021/12/restore-medical.jpg"
imageCredit: "Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/contraband-pulmonary-artery-banding-system-fda-breakthrough/"
---

![ContraBand pulmonary artery banding system gains US FDA breakthrough status for HFrEF treatment](https://cardiovascularnews.com/wp-content/uploads/sites/14/2021/12/restore-medical.jpg)

*Crédit image : Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/contraband-pulmonary-artery-banding-system-fda-breakthrough/*

## L’essentiel

Restore Medical has been granted breakthrough device designation by the US Food and Drug Administration (FDA) for its ContraBand device. The designation is specifically for treatment of heart failure with reduced ejection fraction (HFrEF) patients who remain symptomatic despite maximally tolerated guideline-directed medical therapy, without significant pulmonary hypertension or right heart failure.

## Lien source

https://cardiovascularnews.com/contraband-pulmonary-artery-banding-system-fda-breakthrough/
